Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
NBN News Interview
Dr Chris Burns Announced as Co-Recipient of 2024 Prime Minister's Prize for Innovation
Categories
Archive
Company News
Investor Newsletters
Videos
19 Jul 2021
Garvan's June Seminar: The Power of Personalised Medicine
Read More
30 Jun 2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Read More
28 Jun 2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Read More
02 Jun 2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
Read More
18 Mar 2021
Amplia Therapeutics signs agreement with Garvan Institute
Read More
17 Mar 2021
Amplia Therapeutics completes single-dose study of AMP945
Read More
14 Oct 2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
1
2
3
4
5
6
